Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/15/2019 05/16/2019 05/17/2019 05/20/2019 05/21/2019 Date
78.89(c) 80(c) 79.03(c) 76.68(c) 78.52 Last
562 497 480 612 744 148 609 347 587 982 Volume
+0.10% +1.41% -1.21% -2.97% +2.40% Change
More quotes
Financials (USD)
Sales 2019 677 M
EBIT 2019 -0,97 M
Net income 2019 -21,2 M
Finance 2019 485 M
Yield 2019 -
Sales 2020 945 M
EBIT 2020 299 M
Net income 2020 272 M
Finance 2020 565 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 27,30
EV / Sales2019 9,62x
EV / Sales2020 6,81x
Capitalization 7 000 M
More Financials
Company
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are... 
More about the company
Surperformance© ratings of Neurocrine Biosciences, In
Trading Rating : Investor Rating :
More Ratings
Latest news on NEUROCRINE BIOSCIENCES, IN
08:47aNEUROCRINE BIOSCIENCES : Presents New Data from RE-KINECT, the Largest Real-Worl..
AQ
05/16NEUROCRINE BIOSCIENCES : Myovants relugolix clears first uterine fibroids PhIII ..
AQ
05/07NEUROCRINE BIOSCIENCES : to Present at Bank of America Merrill Lynch Health Care..
PR
05/07NEUROCRINE BIOSCIENCES : Honors Mental Health Month and Raises Awareness of Tard..
AQ
05/07NEUROCRINE BIOSCIENCES : Presents Phase III Data Analysis Demonstrating that Opi..
AQ
05/06NEUROCRINE BIOSCIENCES : Presents Phase III Data Analysis Demonstrating that Opi..
AQ
05/06NEUROCRINE BIOSCIENCES : and Voyager Therapeutics Announce Phase I Results for V..
AQ
04/30NEUROCRINE BIOSCIENCES : to Present Data Analyses on INGREZZA® (valbenazine) and..
PU
04/29NEUROCRINE BIOSCIENCES : Management's Discussion and Analysis of Financial Condi..
AQ
04/29NEUROCRINE : 1Q Earnings Snapshot
AQ
More news
Analyst Recommendations on NEUROCRINE BIOSCIENCES, IN
More recommendations
Sector news : Bio Therapeutic Drugs
12:51aGlobal chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Bio Therapeutic Drugs
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 108 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.7.38%7 000
GILEAD SCIENCES5.29%83 745
VERTEX PHARMACEUTICALS1.82%42 447
REGENERON PHARMACEUTICALS-18.99%32 595
GENMAB8.10%10 631
SAREPTA THERAPEUTICS INC7.73%8 718